Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefuroxime + roxithromycin is an antibiotic combination used primarily for treating bacterial infections. This combination pairs cefuroxime, a second-generation cephalosporin antibiotic, with roxithromycin, a macrolide antibiotic, to provide broad-spectrum coverage against various pathogens. ### Mechanism of Action This combination works through complementary mechanisms: - **Cefuroxime** prevents the formation of bacterial cell walls by binding to penicillin-binding proteins, which are essential for bacterial survival[7]. It is particularly effective against many gram-positive and some gram-negative bacteria. - **Roxithromycin** stops bacterial growth by inhibiting protein synthesis. It works by binding to the 50S subunit of bacterial ribosomes, preventing the synthesis of essential proteins required by bacteria to carry out vital functions[2]. ### Clinical Applications The combination has been studied for various infections, including: - **Preterm premature rupture of membranes**: Research has shown that cefuroxime + roxithromycin may be more effective than ampicillin + roxithromycin in prolonging pregnancy in primiparas and reducing maternal and neonatal morbidity[1]. - **Respiratory tract infections**: The individual components have been used for community-acquired pneumonia, with studies comparing roxithromycin with cefixime (another cephalosporin) showing comparable efficacy[3]. ### Dosing While specific dosing for the combination varies by indication, the components are typically administered as: - **Cefuroxime**: 750 mg to 1.5 g intravenously every 8 hours for severe infections, or 250-500 mg orally every 12 hours for less severe cases[10][8]. - **Roxithromycin**: Usually administered at 300 mg once daily[3]. ### Side Effects Common side effects of this antibiotic combination may include: - Gastrointestinal disturbances (nausea, vomiting, diarrhea) - Stomach pain - Flatulence - Indigestion - Loss of appetite[2] ### Drug Interactions Both components have potential drug interactions: - **Cefuroxime** may interact with antacids, BCG intravesical, gout medications like probenecid, immunosuppressants, and certain indigestion medications[7]. - The combination should be used with caution in patients taking other medications, as interactions could affect efficacy or increase side effects. This antibiotic combination represents a therapeutic approach that leverages the complementary mechanisms of two different antibiotic classes to provide enhanced coverage against bacterial pathogens, particularly in cases where resistance to a single agent might be a concern.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cefuroxime + Roxithromycin.